3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Endometrial Neoplasms
1
Carcinoma, Endometrioid
1
Adenomyosis
1
Interventions
Specimen Handling
218
Magnetic Resonance Spectroscopy
194
pembrolizumab
185
Carboplatin
160
Biopsy
129
Cisplatin
128
Nivolumab
119
Paclitaxel
107
Cyclophosphamide
104
Radiotherapy
99
Gemcitabine
96
Dexamethasone
86
durvalumab
83
atezolizumab
70
Rituximab
66
Radiation
64
Lenalidomide
64
Doxorubicin
63
Pemetrexed
61
Bevacizumab
58
Etoposide
56
Docetaxel
56
olaparib
50
Ipilimumab
49
Fluorouracil
48
Taxes
47
Prednisone
47
Oxaliplatin
46
Vincristine
45
Cytarabine
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Hysterectomy
×
90 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled
NCT02598219
2026-03-18
SENTIRAD
Centre Oscar Lambret
Phase 3
Active not recruiting
262 enrolled